Peroxisome proliferator‐activated receptor‐γ abrogates Smad‐dependent collagen stimulation by targeting the p300 transcriptional coactivator

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The FASEB Journal

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1096/fj.08-128736PMID 19395477PMCID PMC2735362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

  2009cited by this paper
• Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis

  2008cited by this paper
• Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways.

  2008cited by this paper
• Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

  2008cited by this paper
• Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma.

  2008cited by this paper
• Pharmacological application of caffeine inhibits TGF-b-stimulated connective tissue growth factor expression in hepatocytes via PPAR c and SMAD 2 / 3-dependent pathways q

  2008cited by this paper
• Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis

  2008cited by this paper
• Peroxisome Proliferator-activated Receptor γ Interacts with CIITA·RFX5 Complex to Repress Type I Collagen Gene Expression*

  2007cited by this paper
• Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.

  2007cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

  2007cited by this paper
• The Role of PPARs in Lung Fibrosis

  2007cited by this paper
• The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis

  2007cited by this paper
• Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer

  2007cited by this paper
• Pioglitazone Induces Apoptosis in Human Vascular Smooth Muscle Cells from Diabetic Patients Involving the Transforming Growth Factor-β/Activin Receptor-Like Kinase-4/5/7/Smad2 Signaling Pathway

  2007cited by this paper
• PPARs and molecular mechanisms of transrepression.

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression.

  2007cited by this paper
• Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10).

  2006cited by this paper
• Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta).

  2006cited by this paper
• Inhibition of collagen gene expression by interferon‐γ: Novel role of the CCAAT/enhancer binding protein β (C/EBPβ)

  2006cited by this paper
• Transcriptional regulation of the human alpha2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases.

  2006cited by this paper
• Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription

  2006cited by this paper
• PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

  2006cited by this paper
• hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.

  2006cited by this paper
• Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone

  2006cited by this paper
• PPARγ Agonists Prevent TGFβ1/Smad3-Signaling in Human Hepatic Stellate Cells

  2006cited by this paper
• Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts.

  2006cited by this paper
• Peroxisome Proliferator-activated Receptor γ Suppresses Proximal α1(I) Collagen Promoter via Inhibition of p300-facilitated NF-I Binding to DNA in Hepatic Stellate Cells*

  2005cited by this paper
• PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.

  2005cited by this paper
• Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury

  2005cited by this paper
• PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis

  2005cited by this paper
• PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.

  2005cited by this paper
• Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.

  2005cited by this paper
• Hepatocyte Growth Factor Is a Downstream Effector that Mediates the Antifibrotic Action of Peroxisome Proliferator–Activated Receptor-γ Agonists

  2005cited by this paper
• The many faces of PPARgamma.

  2005cited by this paper
• Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.

  2005cited by this paper
• Smad transcription factors.

  2005cited by this paper
• Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism.

  2005cited by this paper
• Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells.

  2005cited by this paper
• The Tumor Suppressor p53 Abrogates Smad-dependent Collagen Gene Induction in Mesenchymal Cells*

  2004cited by this paper
• Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.

  2004cited by this paper
• Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts.

  2003cited by this paper
• Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

  2003cited by this paper
• Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

  2002cited by this paper
• The mechanisms of action of PPARs.

  2002cited by this paper
• Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain.

  2002cited by this paper
• Overexpression and Ribozyme-mediated Targeting of Transcriptional Coactivators CREB-binding Protein and p300 Revealed Their Indispensable Roles in Adipocyte Differentiation through the Regulation of Peroxisome Proliferator-activated Receptor γ*

  2002cited by this paper
• Factors Involved in the Regulation of Type I Collagen Gene Expression: Implication in Fibrosis

  2002cited by this paper
• Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.

  2002cited by this paper
• Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

  2002cited by this paper
• Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation

  2002cited by this paper
• Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain.

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.

  2001cited by this paper
• CREB-binding Protein and p300 in Transcriptional Regulation*

  2001cited by this paper
• Cyclopentenone prostaglandins: New insights on biological activities and cellular targets

  2001cited by this paper
• PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

  2001cited by this paper
• Antagonistic Regulation of Type I Collagen Gene Expression by Interferon-γ and Transforming Growth Factor-β

  2001cited by this paper
• Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators.

  2001cited by this paper
• Ligand type-specific Interactions of Peroxisome Proliferator-activated Receptor γ with Transcriptional Coactivators*

  2000cited by this paper
• Peroxisome Proliferator-Activated Receptor γ-Dependent Repression of the Inducible Nitric Oxide Synthase Gene

  2000cited by this paper
• Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta.

  2000cited by this paper
• Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.

  2000cited by this paper
• Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators

  2000cited by this paper
• Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3.

  1999cited by this paper
• PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development

  1999cited by this paper
• p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively.

  1999cited by this paper
• p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively*

  1999cited by this paper
• PPAR gamma is required for placental, cardiac, and adipose tissue development.

  1999cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Human Smad3 and Smad4 are sequence-specific transcription activators.

  1998cited by this paper
• Regulation of activity of the transcription factor GATA-1 by acetylation

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Human Smad3 and Smad4 Are Sequence-Specific Transcription Activators

  1998influential reference
• Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells.

  1997cited by this paper
• Transcriptional Regulation of the Human α2(I) Collagen Gene

  1996cited by this paper
• A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.

  1996cited by this paper

• The Mechanistic Role of PPARγ in Wound Healing

  2026cites this paper
• Exposure to PFOA and GenX elicits cell type-specific impacts on p53 and TGF-β signaling pathways

  2026cites this paper
• Lathyrol Exerts Anti-Pulmonary Fibrosis Effects by Activating PPARγ to Inhibit the TGF-β/Smad Pathway

  2025cites this paper
• Epigenetic reprogramming via EZH2 inhibition rescues fibroadipose pathogenesis in secondary lymphedema through activating PPARγ signaling

  2025cites this paper
• 12/15-lipoxygenase orchestrates murine wound healing via PPARγ-activating oxylipins acting holistically to dampen inflammation

  2025cites this paper
• Atgl-dependent adipocyte lipolysis promotes lipodystrophy and restrains fibrogenic responses during skin fibrosis.

  2025cites this paper
• The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis

  2024cites this paper
• PPAR gamma agonistic activity of dillapiole: protective effects against diabetic nephropathy

  2024cites this paper
• PPARs: modulating lipotoxicity and thus inhibiting fibrosis

  2024influential citation
• Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

  2023cites this paper
• EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs

  2023cites this paper
• Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation.

  2022cites this paper
• Protective effects and mechanisms of lycorine against adriamycin-induced cardiotoxicity.

  2022cites this paper
• Frontal fibrosing alopecia: A review of disease pathogenesis

  2022cites this paper
• Cannabidiol markedly alleviates skin and liver fibrosis

  2022cites this paper
• Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease

  2022cites this paper
• The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders

  2021cites this paper
• Acetyltransferase p300 Is a Putative Epidrug Target for Amelioration of Cellular Aging-Related Cardiovascular Disease

  2021cites this paper
• Pharmacology and therapeutics: Review Pharmacological activation of PPAR-c: a potential therapy for skin fibrosis

  2021cites this paper
• PPAR-y agonists promote the resolution of myelofibrosis in preclinical models.

  2021cites this paper
• Cellular and molecular mechanisms in fibrosis

  2020cites this paper
• Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope

  2020cites this paper
• Plumbagin Suppresses Pulmonary Fibrosis via Inhibition of p300 Histone Acetyltransferase Activity

  2020cites this paper
• TGF-β1 attenuates mitochondrial bioenergetics in pulmonary arterial endothelial cells via the disruption of carnitine homeostasis

  2020cites this paper
• Deciphering the significant role of various gene expression in modulating the toughness of bovine muscle

  2020cites this paper
• Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies

  2020cites this paper
• HDAC8 inhibition ameliorates pulmonary fibrosis.

  2019cites this paper
• Role of the cytoskeleton in the development of a hypofibrotic cardiac fibroblast phenotype in volume overload heart failure.

  2019cites this paper
• TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts

  2019cites this paper
• PPAR‐γ signalling as a key mediator of human hair follicle physiology and pathology

  2019cites this paper
• Molecular determinants of mesenchymal cell activation in fibroproliferative diseases

  2019cites this paper
• The Effect of Quercetin for Salt Induces Renal Fibrosis by Suppressing Collagen Production

  2019cites this paper
• Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists

  2019cites this paper
• 15-Deoxy-Δ-12, 14-prostaglandin J2 acts cooperatively with prednisolone to reduce TGF-β-induced pro-fibrotic pathways in human osteoarthritis fibroblasts.

  2019cites this paper
• Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts

  2019cites this paper
• Cannabinoid derivatives acting as dual PPAR&ggr;/CB2 agonists as therapeutic agents for systemic sclerosis

  2019cites this paper
• VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways

  2018cites this paper
• The effect of maternal exposure to di‐(2‐ethylhexyl)‐phthalate on fetal cardiac development in mice

  2018cites this paper
• The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders

  2018cites this paper
• EHP‐101, an oral formulation of the cannabidiol aminoquinone VCE‐004.8, alleviates bleomycin‐induced skin and lung fibrosis

  2018cites this paper
• Frontiers of antifibrotic therapy in systemic sclerosis

  2018cites this paper
• BET Proteins: An Approach to Future Therapies in Transplantation

  2017cites this paper
• Drugs and Targets in Fibrosis

  2017cites this paper
• Epigenetic factors as drivers of fibrosis in systemic sclerosis.

  2017cites this paper
• Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension

  2017cites this paper
• Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy

  2017influential citation
• The Myofibroblast: TGFβ-1, A Conductor which Plays a Key Role in Fibrosis by Regulating the Balance between PPARγ and the Canonical WNT Pathway

  2017cites this paper
• Telmisartan Prevents Myocardial Fibrosis via Decreasing Fraction of Colagen Type 1 Volume in Myocardial Tissue in Wistar Rats-Induced High Salt Intake

  2017cites this paper
• Activated p300 acetyltransferase activity modulates aortic valvular calcification with osteogenic transdifferentiation and downregulation of Klotho.

  2017cites this paper
• Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities

  2017cites this paper
• Pathophysiology of Fibrosis in Systemic Sclerosis

  2017cites this paper
• Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis

  2017cites this paper
• Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis

  2017cites this paper
• A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis

  2017cites this paper
• Puerarin Protects against Cardiac Fibrosis Associated with the Inhibition of TGF-β1/Smad2-Mediated Endothelial-to-Mesenchymal Transition

  2017cites this paper
• Protective effect of α-lipoic acid against radiation-induced fibrosis in mice

  2016cites this paper
• The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways

  2016cites this paper
• Novel PPAR&ggr; Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis

  2016cites this paper
• Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis

  2016cites this paper
• DHEA and frontal fibrosing alopecia: molecular and physiopathological mechanisms

  2016cites this paper
• Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.

  2015cites this paper
• Profibrotic Transcriptome Signature Macrophage Epoxygenase Determines a

  2015cites this paper
• Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts

  2015cites this paper
• in Physiology and Disease PPAR Modulation of Kinase-Linked Receptor Signaling

  2015cites this paper
• Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

  2015cites this paper
• Lipids and Skin Health

  2015cites this paper
• Telmisartan prevents myocardial fibrosis : telmisartan decreases tgf-β1 and collagen fraction volume myocardial tissue in wistar rats induced high salt intake

  2015cites this paper
• The Role of PPAR Gamma in Systemic Sclerosis

  2015cites this paper
• Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

  2015cites this paper
• Smooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and Function

  2015cites this paper
• The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling

  2015cites this paper
• PPAR Gamma Receptor, Skin Lipids and Hair

  2015cites this paper
• Macrophage Epoxygenase Determines a Profibrotic Transcriptome Signature

  2015cites this paper
• Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation.

  2014cites this paper
• The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β and Contributes to the Development of Experimental Dermal Fibrosis

  2014cites this paper
• Fibrosis—a lethal component of systemic sclerosis

  2014cites this paper
• Fibrosis—a lethal component of systemic

  2014cites this paper
• FAT‐Free p300 Is Good for Scar‐Free Tissue Repair

  2014cites this paper
• Vascular fibrosis in atherosclerosis.

  2013cites this paper
• BET Bromodomain Proteins Mediate Downstream Signaling Events following Growth Factor Stimulation in Human Lung Fibroblasts and Are Involved in Bleomycin-Induced Pulmonary Fibrosis

  2013influential citation
• Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.

  2013cites this paper
• A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses

  2013cites this paper
• Strategies for anti-fibrotic therapies.

  2013cites this paper
• Molecular basis of organ fibrosis: Potential therapeutic approaches

  2013cites this paper
• The Contribution of Peroxisome Proliferator–Activated Receptor Gamma to Cutaneous Wound Healing

  2013cites this paper
• Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype.

  2013cites this paper
• Fibrosis in systemic sclerosis: common and unique pathobiology

  2012cites this paper
• PAI‐1 in tissue fibrosis

  2012influential citation
• Mechanism of Fibrosis

  2012cites this paper
• Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts

  2012cites this paper
• E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model

  2012cites this paper
• Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis

  2012cites this paper
• Interaction between IGF binding protein-3 and TGFβ in the regulation of adipocyte differentiation.

  2012cites this paper
• p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis

  2012cites this paper
• The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy

  2012cites this paper
• Getting Out of a Sticky Situation: Targeting the Myofibroblast in Scleroderma

  2012cites this paper
• Scleroderma therapy: clinical overview of current trends and future perspective

  2012cites this paper
• Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis.

  2012cites this paper
• The complex regulation of TGF-β in cardiovascular disease

  2012cites this paper
• Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

  2012cites this paper